JP2024517693A5 - - Google Patents
Info
- Publication number
- JP2024517693A5 JP2024517693A5 JP2023565515A JP2023565515A JP2024517693A5 JP 2024517693 A5 JP2024517693 A5 JP 2024517693A5 JP 2023565515 A JP2023565515 A JP 2023565515A JP 2023565515 A JP2023565515 A JP 2023565515A JP 2024517693 A5 JP2024517693 A5 JP 2024517693A5
- Authority
- JP
- Japan
- Prior art keywords
- fluoro
- chloro
- quinazoline
- amine
- thiazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163181627P | 2021-04-29 | 2021-04-29 | |
| US63/181,627 | 2021-04-29 | ||
| PCT/US2022/026624 WO2022232332A1 (en) | 2021-04-29 | 2022-04-28 | 2-aminobenzothiazole compounds and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024517693A JP2024517693A (ja) | 2024-04-23 |
| JP2024517693A5 true JP2024517693A5 (https=) | 2025-05-08 |
Family
ID=81654930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023565515A Pending JP2024517693A (ja) | 2021-04-29 | 2022-04-28 | ２－アミノベンゾチアゾール化合物及びその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250059179A1 (https=) |
| EP (1) | EP4329888A1 (https=) |
| JP (1) | JP2024517693A (https=) |
| CN (1) | CN117651700A (https=) |
| AU (1) | AU2022265682A1 (https=) |
| CA (1) | CA3217830A1 (https=) |
| MX (1) | MX2023012725A (https=) |
| WO (1) | WO2022232332A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019195609A2 (en) | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| US20250059205A1 (en) * | 2021-04-29 | 2025-02-20 | Amgen Inc. | Heterocyclic Compounds and Methods of Use |
| WO2022261154A1 (en) * | 2021-06-09 | 2022-12-15 | Eli Lilly And Company | Substituted fused azines as kras g12d inhibitors |
| CN116143805B (zh) * | 2021-09-17 | 2025-10-17 | 上海凌达生物医药有限公司 | 一类含氮杂环联芳基类化合物、制备方法和用途 |
| CN118556063A (zh) * | 2022-01-21 | 2024-08-27 | 上海湃隆生物科技有限公司 | 杂环类化合物、药物组合物及其应用 |
| CA3243798A1 (en) | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras Modulators and Their Uses |
| JP2025510572A (ja) | 2022-03-08 | 2025-04-15 | レボリューション メディシンズ インコーポレイテッド | 免疫不応性肺癌を治療するための方法 |
| WO2023230190A1 (en) | 2022-05-25 | 2023-11-30 | Quanta Therapeutics, Inc. | Pyrimidine based modulators and uses thereof |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024008068A1 (en) * | 2022-07-04 | 2024-01-11 | Jacobio Pharmaceuticals Co., Ltd. | K-ras mutant protein inhibitors |
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| KR20260041941A (ko) | 2023-03-15 | 2026-03-27 | 콴타 테라퓨틱스, 인크. | Kras 조절 인자 및 이의 용도 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CR20250420A (es) | 2023-04-07 | 2025-11-20 | Revolution Medicines Inc | Inhibidores macrocíclicos de ras |
| AR132338A1 (es) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | Inhibidores de ras |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| CN121464140A (zh) | 2023-04-14 | 2026-02-03 | 锐新医药公司 | Ras抑制剂的结晶形式、含有其的组合物及其使用方法 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| TW202529804A (zh) | 2023-10-06 | 2025-08-01 | 美商安進公司 | 用於癌症治療的組合療法 |
| CN121969634A (zh) * | 2023-10-08 | 2026-05-01 | 成都海博为药业有限公司 | 一种稠环化合物及应用 |
| US20250114339A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor |
| US20250114346A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4302834A3 (en) | 2016-07-12 | 2024-07-17 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| JP7240319B2 (ja) | 2017-01-23 | 2023-03-15 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としての二環式化合物 |
| KR20190110588A (ko) | 2017-01-23 | 2019-09-30 | 레볼루션 메디슨즈, 인크. | 알로스테릭 shp2 억제제로서의 피리딘 화합물 |
| AU2018273356B2 (en) | 2017-05-22 | 2021-09-16 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| AU2018329920B2 (en) | 2017-09-08 | 2022-12-01 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
| TW201930292A (zh) | 2017-10-12 | 2019-08-01 | 美商銳新醫藥公司 | 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物 |
| TW202033518A (zh) * | 2018-10-15 | 2020-09-16 | 美商美國禮來大藥廠 | Kras g12c 抑制劑 |
| MA54543A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Inhibiteurs de kif18a |
| JP2022513967A (ja) | 2018-12-20 | 2022-02-09 | アムジエン・インコーポレーテツド | Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド |
| AU2019401495B2 (en) | 2018-12-20 | 2025-06-26 | Amgen Inc. | Heteroaryl amides useful as KIF18A inhibitors |
| JP7686559B2 (ja) | 2018-12-20 | 2025-06-02 | アムジエン・インコーポレーテツド | Ｋｉｆ１８ａ阻害剤 |
| MX2022002465A (es) * | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| CA3177261A1 (en) * | 2020-04-29 | 2021-11-04 | Shanghai Ringene Biopharma Co., Ltd. | Benzothiazolyl biaryl compound, and preparation method and use |
| WO2022002102A1 (en) * | 2020-06-30 | 2022-01-06 | InventisBio Co., Ltd. | Quinazoline compounds, preparation methods and uses thereof |
| CA3191279A1 (en) * | 2020-08-28 | 2022-03-03 | Yi Liu | Heterocyclic compounds and uses thereof |
| CN120887884A (zh) * | 2020-11-06 | 2025-11-04 | 泰励生物科技（上海）有限公司 | 用于癌症治疗的KRas抑制剂 |
| KR20230136636A (ko) * | 2021-02-09 | 2023-09-26 | 메드샤인 디스커버리 아이엔씨. | 피리미딘 방향족 환 화합물 |
| EP4291199A4 (en) * | 2021-02-09 | 2025-06-18 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| BR112023016299A2 (pt) * | 2021-02-16 | 2023-11-28 | L Livermore Nat Security Llc | Composições e métodos para inibir kras |
-
2022
- 2022-04-28 MX MX2023012725A patent/MX2023012725A/es unknown
- 2022-04-28 JP JP2023565515A patent/JP2024517693A/ja active Pending
- 2022-04-28 CN CN202280046357.6A patent/CN117651700A/zh active Pending
- 2022-04-28 US US18/696,948 patent/US20250059179A1/en active Pending
- 2022-04-28 AU AU2022265682A patent/AU2022265682A1/en active Pending
- 2022-04-28 WO PCT/US2022/026624 patent/WO2022232332A1/en not_active Ceased
- 2022-04-28 CA CA3217830A patent/CA3217830A1/en active Pending
- 2022-04-28 EP EP22723911.8A patent/EP4329888A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024517693A5 (https=) | ||
| US12037345B2 (en) | Heterobicyclic compounds for inhibiting the activity of SHP2 | |
| JP2024532734A5 (https=) | ||
| US20260015350A1 (en) | Azaquinazoline pan-kras inhibitors | |
| AU2019240299B2 (en) | SHP2 phosphatase inhibitors and methods of use thereof | |
| AU2022265682A1 (en) | 2-aminobenzothiazole compounds and methods of use thereof | |
| KR101812357B1 (ko) | Ｃｄｋ4/6의 억제제로서의 피롤로피리미딘 화합물 | |
| JP2025525355A (ja) | テトラヒドロピリドピリミジン汎ＫＲａｓ阻害剤 | |
| ES2687477T3 (es) | Inhibidor de quinasa y su uso | |
| JP2011500774A5 (https=) | ||
| JP2020522570A5 (https=) | ||
| RU2012142551A (ru) | Ингибиторы пирролопиразинкиназы | |
| JP2023543433A5 (https=) | ||
| JP2024517740A5 (https=) | ||
| TW202334166A (zh) | 螺三環ripk1抑制劑及其使用方法 | |
| EA042323B1 (ru) | Гетеробициклические соединения для ингибирования активности shp2 | |
| IL325247A (en) | History of 3-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]-8,3-diazabicyclo[3.2.1]octane as a protacs from SMARCA2 joints for cancer treatment | |
| NZ737297A (en) | Bicyclic lactams and methods of use thereof | |
| NZ737297B2 (en) | Bicyclic lactams and methods of use thereof |